Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. Active clinical trials are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.
In this podcast, Timothy Gilligan, MD, FASCO, leads a discussion with Neeraj Agarwal, MD; Petros Grivas, MD, PhD; and Tian Zhang, MD, about 3 clinical trials in kidney, bladder, and prostate cancer.
The CheckMate 914 phase III clinical trial is studying whether using an immunotherapy drug either alone or in combination with another immunotherapy drug can prevent or delay kidney cancer from coming back after surgery . [3:40]
The KEYNOTE-992 phase III clinical trial is evaluating whether adding an immunotherapy drug to the combination of chemotherapy and radiation therapy in people with muscle-invasive bladder cancer can prevent the need for surgical removal of the bladder. [8:31]
The KEYNOTE-991 phase III clinical trial is testing whether adding an immunotherapy drug to hormonal therapy for people with newly diagnosed metastatic castration-sensitive prostate cancer helps them live longer and delays tumor growth. [15:44]
Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Agarwal is the senior director of clinical research innovation at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine, an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an associate professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers.
Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked in the paragraph above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.